VIFOR-PHARMA
2.2.2021 07:02:08 CET | Business Wire | Press release
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Alexandre LeBeaut was formerly Chief Scientific Officer and Executive Vice-President R&D at Ipsen Bioscience Inc. with more than 25 years of extensive global R&D experience in the biopharmaceutical industry including Schering-Plough, Novartis, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. Alexandre is a French and US citizen and a pediatrician who holds a M.D. from Paris University. He is a member of the Board of Calypso Biotech.
After 25 years with Vifor Pharma and four years of service on the Board of Directors, Dr Gianni Zampieri has decided that he will not stand for re-election to the Board at the Annual General Meeting in 2021. “With his expertise and valuable insights, Gianni Zampieri has been instrumental in the strategic development of the company in various roles. Because of his profound strategic foresight he drove the development and the launch of Ferinject, which is now a blockbuster product for the company.” As CEO for Vifor Pharma he successfully managed the separation of the group and the IPO of Galenica. Gilbert Achermann has also decided to step down from the Board of Vifor Pharma and therefore does not stand for re-election. “On behalf of the Board of Directors, I extend our sincere gratitude to both Directors for their excellent and successful work for Vifor Pharma, and we wish them all the best for their private and professional future” said Jacques Theurillat.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005792/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
Quectel Expands RG660Qx 5G Module Capabilities for Future Railway Mobile Communication System Evaluation and Railway Applications3.9.2026 10:00:00 CEST | Press release
High-performance Sub-6GHz 5G module platform with support for FRMCS-related frequency bands enables early evaluation through a dedicated development environment. Quectel Wireless Solutions, a global IoT solutions provider, today announced an LGA version of its RG660Qx 5G module series, a high performance, Sub-6GHz 5G module platform that includes support for the Future Railway Mobile Communication System (FRMCS). Used with a dedicated evaluation environment comprising an adaptor board and EVB Kit, the RG660Qx enables equipment manufacturers and railway technology developers to conduct early Future Railway Mobile Communication System (FRMCS) evaluation and testing, supporting development ahead of the transition from GSM-R. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903961434/en/ Quectel expands RG660Qx 5G module capabilities for Future Railway Mobile Communication System evaluation and railway applications The Future R
Belkin introducerer fremtidens bærbare strømforsyning med nye UltraCharge Pro Power Banks med halvfaste celler3.9.2026 10:00:00 CEST | Pressemeddelelse
Den næste generation af bærbar strømforsyning præsenteres for første gang på IFA 2026 og fremviser avanceret BoostSolid Cell-teknologi og ultraslanke design Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag nye bærbare opladningsløsninger baseret på halvfast celleteknologi. Den nye UltraCharge Pro med BoostSolid Cell-serie er blandt Belkins første produkter med halvfast celleteknologi, et batteri af næste generation, der leverer forbedret holdbarhed, slankt design og længere batteritid – alt sammen uden at gå på kompromis med ydeevnen. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903417354/da/ Product image showcasing the first two Belkin power banks launched with BoostSolid technology Batteriteknologi af næste generation til længerevarende
I’m green™ bio-based Helps Deterra® Win Multiple Industry Awards for Pharmaceutical Packaging3.9.2026 10:00:00 CEST | Press release
The Deterra® Drug Disposal Pouch, which is made with 50% or more I'm green™ bio-based polymer, has gained Accredo Packaging a number of leading packing industry awards. Developed by Verde, the patented drug disposal technology is designed to deactivate unused medications, preventing drug diversion and mitigating the risk of pharmaceuticals leaching into groundwater and waterways. The partial use of I’m green™ bio-based polymer derived from renewable sugarcane, reduces the carbon footprint of the packaging material compared to equivalent fossil-based polyethylene, all whilst maintaining the technical performance required for pharmaceutical disposal applications. Material Innovation and Application The Deterra® pouch required a material that could meet strict technical specifications without relying entirely on traditional, fossil-based plastics. By utilizing I’m green™ bio‑based polyethylene, the packaging has a reduced carbon footprint whilst maintaining the performance of conventional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom